Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bruce

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Nutrition (Burbank, Los Angeles County, Calif.)|March 8, 2002
Glutamine: an anaplerotic precursorJoanna L Bowtell, Mark Bruce
Toxicology and Applied Pharmacology|November 4, 2008
Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potencyRaghuraman Venkatapathy, Ching Yi Wang, Robert Mark Bruce, et al.
Regulatory Toxicology and Pharmacology : RTP|October 19, 2010
Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals. II. Using oral slope factor as a measure of carcinogenic potencyNina Ching Yi Wang, Raghuraman Venkatapathy, Robert Mark Bruce, et al.
Clinical Therapeutics|August 8, 2015
Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy VolunteersFumitaka Suto, Andrew T Wood, Michiyoshi Kobayashi, et al.
Sports Medicine (Auckland, N.Z.)|November 22, 2007
Tricarboxylic acid cycle intermediate pool size: functional importance for oxidative metabolism in exercising human skeletal muscleJoanna L Bowtell, Simon Marwood, Mark Bruce, et al.
Stereotactic and Functional Neurosurgery|August 12, 2016
Outcomes in Patients with Vestibular Schwannoma after Subtotal Resection and Adjuvant RadiosurgeryHesham Radwan, Mark Bruce Eisenberg, Jonathan Petrus Sandberg Knisely, et al.
British Journal of Clinical Pharmacology|January 15, 2021
ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human studyDominic Beale, Jeremy Dennison, Malcolm Boyce, et al.
Global Challenges (Hoboken, NJ)|January 21, 2020
Quantification of Trace Mercury in Water: Solving the Problem of Adsorption, Sample Preservation, and Cross-ContaminationJingqi Zhang, Jingbo Chao, Yang Tang, et al.
Bone|February 28, 2016
Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeysHiroyuki Yamada, Yasuo Ochi, Hiroshi Mori, et al.
Synapse (New York, N.Y.)|March 1, 2017
Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [<sup>11</sup> C]PBR28W Gordon Frankle, Rajesh Narendran, Andrew T Wood, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nutrition (Burbank, Los Angeles County, Calif.)|March 8, 2002
Glutamine: an anaplerotic precursorJoanna L Bowtell, Mark Bruce
Toxicology and Applied Pharmacology|November 4, 2008
Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potencyRaghuraman Venkatapathy, Ching Yi Wang, Robert Mark Bruce, et al.
Regulatory Toxicology and Pharmacology : RTP|October 19, 2010
Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals. II. Using oral slope factor as a measure of carcinogenic potencyNina Ching Yi Wang, Raghuraman Venkatapathy, Robert Mark Bruce, et al.
Clinical Therapeutics|August 8, 2015
Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy VolunteersFumitaka Suto, Andrew T Wood, Michiyoshi Kobayashi, et al.
Sports Medicine (Auckland, N.Z.)|November 22, 2007
Tricarboxylic acid cycle intermediate pool size: functional importance for oxidative metabolism in exercising human skeletal muscleJoanna L Bowtell, Simon Marwood, Mark Bruce, et al.
Stereotactic and Functional Neurosurgery|August 12, 2016
Outcomes in Patients with Vestibular Schwannoma after Subtotal Resection and Adjuvant RadiosurgeryHesham Radwan, Mark Bruce Eisenberg, Jonathan Petrus Sandberg Knisely, et al.
British Journal of Clinical Pharmacology|January 15, 2021
ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human studyDominic Beale, Jeremy Dennison, Malcolm Boyce, et al.
Global Challenges (Hoboken, NJ)|January 21, 2020
Quantification of Trace Mercury in Water: Solving the Problem of Adsorption, Sample Preservation, and Cross-ContaminationJingqi Zhang, Jingbo Chao, Yang Tang, et al.
Bone|February 28, 2016
Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeysHiroyuki Yamada, Yasuo Ochi, Hiroshi Mori, et al.
Synapse (New York, N.Y.)|March 1, 2017
Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [<sup>11</sup> C]PBR28W Gordon Frankle, Rajesh Narendran, Andrew T Wood, et al.
Pageof 2